Zhejiang Shapuaisi PharmaceuticalLtd Valuation
Is 603168 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 603168 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 603168 (CN¥9.19) wird über unserer Schätzung des Fair Value (CN¥0.78) gehandelt.
Deutlich unter dem Marktwert: 603168 über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 603168?
Other financial metrics that can be useful for relative valuation.
| What is 603168's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥3.75b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.5x |
| Enterprise Value/EBITDA | 30.5x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 603168's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.7x | ||
300434 Sichuan Goldstone Asia Pharmaceutical | 14.9x | n/a | CN¥3.7b |
301277 Newland Pharmaceutical | 22.9x | n/a | CN¥3.6b |
003020 Hefei Lifeon Pharmaceutical | 16.1x | 19.6% | CN¥3.4b |
600613 Shanghai Shenqi Pharmaceutical Investment Management | 60.9x | n/a | CN¥3.5b |
603168 Zhejiang Shapuaisi PharmaceuticalLtd | 46.8x | n/a | CN¥3.7b |
Price-To-Earnings gegen Gleichaltrige: 603168 ist auf der Grundlage des Price-To-Earnings Verhältnisses (43.5x) im Vergleich zum Durchschnitt der Vergleichsgruppe (28.3x) teuer.
Price to Earnings Ratio vs Industry
How does 603168's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price-To-Earnings gegen Industrie: 603168 ist teuer, wenn man sein Price-To-Earnings Verhältnis (43.5x) mit dem CN Pharmaceuticals Branchendurchschnitt (25.4x) vergleicht.
Price to Earnings Ratio vs Fair Ratio
What is 603168's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 46.8x |
| Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von 603168 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.